L V Gubareva

Summary

Affiliation: University of Virginia
Country: USA

Publications

  1. ncbi request reprint Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay
    Larisa V Gubareva
    Department of Internal Medicine, Division of Epidemiology and Virology, University of Virginia School of Medicine, P O Box 800473, Charlottesville, VA 22908 0473, USA
    Antiviral Res 53:47-61. 2002
  2. ncbi request reprint Influenza A (H1N1) virus resistance to cyanovirin-N arises naturally during adaptation to mice and by passage in cell culture in the presence of the inhibitor
    Donald F Smee
    Institute for Antiviral Research, Utah State University, Logan, UT, USA
    Antivir Chem Chemother 18:317-27. 2007
  3. ncbi request reprint Influenza virus neuraminidase inhibitors
    L V Gubareva
    Department of Internal Medicine, University of Virginia, School of Medicine, Charlottesville 22908, USA
    Lancet 355:827-35. 2000
  4. ncbi request reprint Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors
    Larisa V Gubareva
    Department of Internal Medicine, University of Virginia Health Sciences Center, P O Box 800473, Charlottesville, VA, USA
    Virus Res 103:199-203. 2004
  5. ncbi request reprint Assessment of hemagglutinin sequence heterogeneity during influenza virus transmission in families
    Larisa V Gubareva
    Department of Internal Medicine, University of Virginia School of Medicine Health Sciences System, Charlottesville 22908, USA
    J Infect Dis 186:1575-81. 2002
  6. ncbi request reprint A release-competent influenza A virus mutant lacking the coding capacity for the neuraminidase active site
    Larisa V Gubareva
    Department of Internal Medicine, University of Virginia, 1300 Jefferson Park Avenue, Jordan Hall Room 2231, PO Box 800473, Charlottesville 22908, USA
    J Gen Virol 83:2683-92. 2002
  7. pmc Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants
    L V Gubareva
    Division of Epidemiology and Virology, Department of Internal Medicine, University of Virginia School of Medicine, Charlottesville, Virginia 22908, USA
    Antimicrob Agents Chemother 45:3403-8. 2001
  8. ncbi request reprint Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir
    L V Gubareva
    Department of Internal Medicine, Division of Epidemiology and Virology, University of Virginia, PO Box 473, Charlottesville, VA 22908, USA
    J Infect Dis 183:523-31. 2001
  9. ncbi request reprint HA2-specific monoclonal antibodies as tools for differential recognition of influenza A virus antigenic subtypes
    Eva Varečková
    Institute of Virology, Slovak Academy of Sciences, Dubravska cesta 9, 845 05 Bratislava, Slovak Republic
    Virus Res 132:181-6. 2008
  10. ncbi request reprint Hydrophobic polycationic coatings inactivate wild-type and zanamivir- and/or oseltamivir-resistant human and avian influenza viruses
    Jayanta Haldar
    Department of Chemistry and Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
    Biotechnol Lett 30:475-9. 2008

Collaborators

Detail Information

Publications21

  1. ncbi request reprint Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay
    Larisa V Gubareva
    Department of Internal Medicine, Division of Epidemiology and Virology, University of Virginia School of Medicine, P O Box 800473, Charlottesville, VA 22908 0473, USA
    Antiviral Res 53:47-61. 2002
    ..Because variants selected in the presence of one NA inhibitor could be variably resistant to other inhibitors, all three inhibitors should be used in drug susceptibility testing...
  2. ncbi request reprint Influenza A (H1N1) virus resistance to cyanovirin-N arises naturally during adaptation to mice and by passage in cell culture in the presence of the inhibitor
    Donald F Smee
    Institute for Antiviral Research, Utah State University, Logan, UT, USA
    Antivir Chem Chemother 18:317-27. 2007
    ..The mutations reported here causing resistance to CVN are consistent with its known mode of action...
  3. ncbi request reprint Influenza virus neuraminidase inhibitors
    L V Gubareva
    Department of Internal Medicine, University of Virginia, School of Medicine, Charlottesville 22908, USA
    Lancet 355:827-35. 2000
    ..Because of a broader antiviral spectrum, better tolerance, and less potential for emergence of resistance than is seen with the M2 inhibitors, the neuraminidase inhibitors represent an important advance in the treatment of influenza...
  4. ncbi request reprint Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors
    Larisa V Gubareva
    Department of Internal Medicine, University of Virginia Health Sciences Center, P O Box 800473, Charlottesville, VA, USA
    Virus Res 103:199-203. 2004
    ..Because of complexity of mechanisms of virus resistance, further analysis of the viruses recovered from the drug-treated humans is warranted...
  5. ncbi request reprint Assessment of hemagglutinin sequence heterogeneity during influenza virus transmission in families
    Larisa V Gubareva
    Department of Internal Medicine, University of Virginia School of Medicine Health Sciences System, Charlottesville 22908, USA
    J Infect Dis 186:1575-81. 2002
    ..Substantial genetic conservation during virus transmission within households is indicated...
  6. ncbi request reprint A release-competent influenza A virus mutant lacking the coding capacity for the neuraminidase active site
    Larisa V Gubareva
    Department of Internal Medicine, University of Virginia, 1300 Jefferson Park Avenue, Jordan Hall Room 2231, PO Box 800473, Charlottesville 22908, USA
    J Gen Virol 83:2683-92. 2002
    ..Hyperglycosylation of HA is common in influenza A viruses circulating in humans and has the potential to reduce virus sensitivity to NA inhibitors...
  7. pmc Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants
    L V Gubareva
    Division of Epidemiology and Virology, Department of Internal Medicine, University of Virginia School of Medicine, Charlottesville, Virginia 22908, USA
    Antimicrob Agents Chemother 45:3403-8. 2001
    ..We conclude that RWJ-270201 is a potent inhibitor of NAs of wild-type and some zanamivir-resistant or oseltamivir-resistant influenza A and B virus variants...
  8. ncbi request reprint Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir
    L V Gubareva
    Department of Internal Medicine, Division of Epidemiology and Virology, University of Virginia, PO Box 473, Charlottesville, VA 22908, USA
    J Infect Dis 183:523-31. 2001
    ..Thus, HA affinity for receptors is an essential feature of influenza virus susceptibility to NA inhibitors, both in cell culture and in humans...
  9. ncbi request reprint HA2-specific monoclonal antibodies as tools for differential recognition of influenza A virus antigenic subtypes
    Eva Varečková
    Institute of Virology, Slovak Academy of Sciences, Dubravska cesta 9, 845 05 Bratislava, Slovak Republic
    Virus Res 132:181-6. 2008
    ..The ability of HA2-specific antibodies to differentially react with distinct antigenic subtypes can be utilized in development of diagnostics and in the influenza virus surveillance...
  10. ncbi request reprint Hydrophobic polycationic coatings inactivate wild-type and zanamivir- and/or oseltamivir-resistant human and avian influenza viruses
    Jayanta Haldar
    Department of Chemistry and Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
    Biotechnol Lett 30:475-9. 2008
    ....
  11. ncbi request reprint Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide
    Varough M Deyde
    Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    J Infect Dis 196:249-57. 2007
    ..The results of the study highlight the necessity of close monitoring of resistance to existing antivirals as wells as the need for new therapeutics...
  12. ncbi request reprint Evaluation of methyl inosine monophosphate (MIMP) and peramivir activities in a murine model of lethal influenza A virus infection
    Vasiliy P Mishin
    Department of Internal Medicine, University of Virginia Health Sciences System, Charlottesville, USA
    Antiviral Res 71:64-8. 2006
    ..Our results emphasize the need for careful consideration of murine strains and routes of virus challenge in the design of experiments utilizing lethal influenza virus infection...
  13. pmc Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection
    Michael P Malakhov
    NexBio, Inc, 6330 Nancy Ridge Dr, Suite 105, San Diego, CA 92121, USA
    Antimicrob Agents Chemother 50:1470-9. 2006
    ..04 to 0.9 nM. Mouse and ferret studies confirmed significant in vivo efficacy of the sialidase fusion in both prophylactic and treatment modes...
  14. ncbi request reprint Comparative activities of oseltamivir and A-322278 in immunocompetent and immunocompromised murine models of influenza virus infection
    Michael G Ison
    Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia Health Sciences Center, Charlottesville, 22908, USA
    J Infect Dis 193:765-72. 2006
    ..This model would be useful for elucidation of the molecular mechanisms of resistance to NA inhibitors and for testing of anti-influenza therapy options that might prevent the emergence of resistant variants...
  15. ncbi request reprint Recovery of drug-resistant influenza virus from immunocompromised patients: a case series
    Michael G Ison
    Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia Health Sciences Center, Charlottesville, 22908, USA
    J Infect Dis 193:760-4. 2006
    ..We describe a novel Asp198Asn NA mutation in an influenza B virus and its decreased susceptibility to both oseltamivir and zanamivir...
  16. pmc Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors
    Vasiliy P Mishin
    Division of Infectious Diseases and International Health, Department of Internal Medicine, University of Virginia Health Sciences Center, P O Box 800473, 1300 Jefferson Ave, Rm 2231, Charlottesville, Virginia 22908, USA
    Antimicrob Agents Chemother 49:4515-20. 2005
    ..These studies indicate that different patterns of susceptibility and cross-resistance between NA inhibitors may prove important if antiviral resistance to zanamivir and oseltamivir were to emerge...
  17. pmc Effect of hemagglutinin glycosylation on influenza virus susceptibility to neuraminidase inhibitors
    Vasiliy P Mishin
    Department of Internal Medicine, School of Medicine, University of Virginia, Charlottesville, VA, USA
    J Virol 79:12416-24. 2005
    ....
  18. ncbi request reprint Accumulation of defective neuraminidase (NA) genes by influenza A viruses in the presence of NA inhibitors as a marker of reduced dependence on NA
    Marina S Nedyalkova
    Department of Internal Medicine, Division of Epidemiology and Virology, University of Virginia School of Medicine, Charlottesville, VA 22908, USA
    J Infect Dis 185:591-8. 2002
    ..Because of a lack of cell culture-based assays for susceptibility testing of human influenza viruses, detection of DeltaRNA segments should be considered an additional assay for monitoring of NA inhibitor resistance...
  19. pmc Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008
    Tiffany G Sheu
    Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Antimicrob Agents Chemother 52:3284-92. 2008
    ..6% (50/579 isolates). The recent increase in oseltamivir resistance among A(H1N1) viruses isolated from untreated patients raises public health concerns and necessitates close monitoring of resistance to NA inhibitors...
  20. ncbi request reprint Protection afforded by intranasal immunization with the neuraminidase-lacking mutant of influenza A virus in a ferret model
    Vasiliy P Mishin
    Division of Infectious Diseases and International Health, Department of Internal Medicine, Health Sciences Center, University of Virginia, 1300 Jefferson Park Avenue, P O Box 800473, Charlottesville, Virginia 22908, USA
    Vaccine 23:2922-7. 2005
    ..We conclude that the NA as antigen is dispensable in the live attenuated influenza virus vaccine and that the NA-lacking mutant can be used as a virus vector...
  21. ncbi request reprint Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient
    David M Weinstock
    N Engl J Med 348:867-8. 2003